Insuman Comb 30 Solostar (Insulin Human)

Insulin human mimics the natural hormone insulin. It binds to insulin receptors on muscle, fat and liver cells, activating signaling pathways that move glucose‑transport proteins to the cell surface, increase glucose uptake, and suppress liver glucose production, thereby lowering circulating glucose.

The dose of Insuman Comb 30 Solostar is individualized by the prescribing healthcare professional based on the patient’s blood‑glucose profile, diet, activity level and other medications. Patients should follow the prescriber’s instructions and not adjust the dose on their own.

Safety data for insulin human in pregnancy and lactation are limited. It may be used only if the potential benefits to the mother outweigh any possible risks to the fetus or infant, and under close medical supervision.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain handling) and necessary import documentation.

Insuman Comb 30 Solostar contains human insulin in a fixed 30/70 ratio of rapid‑acting to intermediate‑acting components, similar to other premixed products such as NovoRapid Mix 30. Clinical efficacy and safety are comparable, but formulation differences (human vs. analog insulin) may influence individual patient response and hypoglycemia risk.

The product must be stored at 2‑8 °C (refrigerated) in its original carton, protected from light. Do not freeze or shake the vial. Once in use, it may be kept at room temperature for a limited period as indicated on the label, but should be discarded after the recommended in‑use time.

Insuman Comb 30 Solostar is given by subcutaneous injection, typically into the abdomen, thigh or upper arm. The injection site should be rotated to avoid lipodystrophy. Patients should be trained on proper technique, needle length, and timing relative to meals as directed by their healthcare provider.

The most serious risks include severe hypoglycemia, which can lead to seizures or loss of consciousness, and allergic reactions such as anaphylaxis. Rarely, patients may develop insulin antibodies that alter drug effectiveness. Prompt medical attention is required if any of these events occur.

Patients with known hypersensitivity to human insulin or any excipients in the formulation should avoid this product. It is also contraindicated in individuals experiencing hypoglycemia at the time of dosing, and caution is advised for those with severe renal or hepatic impairment until evaluated by a clinician.